Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 May;30(3):177–184. doi: 10.1007/BF01669427

Preparation and analysis of bifunctional immunoconjugates containing monoclonal antibodies OKT3 and BABR1

P David Foglesong 1, Martin A Winkler 1, James O Price 1, Gailen D Marshall 1, Sherie H Reagh 1, Dorothy A Bush 1, Kathleen S Hixson 1, William H West 1
PMCID: PMC11038162  PMID: 2598187

Abstract

OKT3 and BABR1 [anti-(breast tumour) antibody] were conjugated usingN-succinimidyl-3-(2-pyridyldithio)propionate (SPDP). The procedure employed mild reducing conditions for SPDP-BABR1 and short conjugation incubations at 37°C. The bifunctional immunoconjugates thus produced were isolated by HPLC gel filtration on a preparative TSK 3000 SW column. Both intact IgG and F(ab′)2 fragments have been conjugated. The ratio of SPDP to IgG for the optimal yield of dimeric OKT3-BABR1 heteroconjugates was determined to be 2 for OKT3 and 1–2 for BABR1. The OKT3-BABR1 dimers were shown to be bifunctional heteroconjugates by polyacrylamide gel electrophoresis, isoelectric focusing, radial immunodiffusion, and flow cytometry. The binding specificities of the bifunctional heteroconjugates were identical to the specificities of both parent antibodies.

Keywords: Monoclonal Antibody, Propionate, Flow Cytometry, Polyacrylamide, Breast Tumour

References

  • 1.Barr IG, McDonald HR, Buchegger F, von Fliedner V. Lysis of tumour cells by the retargeting of murine cytolytic T lymphocytes with bispecific antibodies. Int J Cancer. 1987;40:423. doi: 10.1002/ijc.2910400323. [DOI] [PubMed] [Google Scholar]
  • 2.Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem. 1976;72:248. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  • 3.Brennan M, Davidson PF, Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science. 1985;229:81. doi: 10.1126/science.3925553. [DOI] [PubMed] [Google Scholar]
  • 4.Bush D, Winkler MA. Iso electric focusing of crosslinked monoclonal antibody heterodimers, homodimers, and derivatized antibodies. J Chromatog (Biomed Appl) 1989;489:303. doi: 10.1016/s0378-4347(00)82908-4. [DOI] [PubMed] [Google Scholar]
  • 5.Carlsson J, Drevin H, Axen R. Protein thiolation and reversible protein-protein conjugation. Biochem J. 1978;173:723. doi: 10.1042/bj1730723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Clausen J. In: Laboratory techniques in biochemistry and molecular biology. Work TS, Work E, editors. Amsterdam: North-Holland; 1969. p. 423. [Google Scholar]
  • 7.Dulbecco R, Vogt M. Plaque formation and isolation of pure lines with poliomyelitis viruses. J Exp Med. 1954;99:167. doi: 10.1084/jem.99.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose. Immunochemistry. 1978;15:429. doi: 10.1016/0161-5890(78)90070-6. [DOI] [PubMed] [Google Scholar]
  • 9.Glennie MJ, McBride HM, Worth AT, Stevenson GT. Preparation and performance of bispecific F(ab'r)2 antibody containing thioether-linked Fab'r fragments. J Immunol. 1987;139:2367. [PubMed] [Google Scholar]
  • 10.Jung G, Honsik CJ, Reisfeld RA, Muller-Eberhard HJ. Activation of human peripheral blood mononuclear cells by anti-T2: killing of tumor target cells coated with anti-target anti-T3 conjugates. Proc Natl Acad Sci USA. 1986;83:4479. doi: 10.1073/pnas.83.12.4479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Karpovsky B, Titus JA, Stephany DA, Segal DM. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fcr receptor antibodies. J Exp Med. 1984;160:1686. doi: 10.1084/jem.160.6.1686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriaphage T4. Nature. 1970;227:680. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  • 13.Liu MA, Kranz DM, Kurnick JT, Boyle LA, Levy R, Eisen HN. Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci USA. 1985;82:8648. doi: 10.1073/pnas.82.24.8648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lotze MT, Roberts K, Custer MC, Segal DA, Rosenberg SA. Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 of anti-Fc receptor crosslinked to antimelanoma antibody: a possible approach to the immunotherapy of human tumours. J Surg Res. 1987;42:580. doi: 10.1016/0022-4804(87)90036-9. [DOI] [PubMed] [Google Scholar]
  • 15.Marshall GD, Foglesong PD, Price JO, Winkler MA, West WH. Increased antigen-specific activity of interleukin-2 activated cells by heteroconjugate antibodies. Immunology and Allergy Clinics of North America. 1988;8:126. [Google Scholar]
  • 16.Morrissey JH. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem. 1981;117:307. doi: 10.1016/0003-2697(81)90783-1. [DOI] [PubMed] [Google Scholar]
  • 17.Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985;316:354. doi: 10.1038/316354a0. [DOI] [PubMed] [Google Scholar]
  • 18.Perez P, Hoffman RW, Titus JA, Segal DM. Specific targeting of human peripheral blood T cells by heteroconjugates containing anti-T3 cross-linked to anti-target cell antibodies. J Exp Med. 1986;163:166. doi: 10.1084/jem.163.1.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Perez P, Titus JA, Lotze MT, Cuttita F, Longo DL, Groves EL, Rabin H, Durda PJ, Segal DM. Specific lysis of human tumour cells by T cells coated with anti-T3 crosslinked to anti-tumour antibody. J Immunol. 1986;137:2069. [PubMed] [Google Scholar]
  • 20.Raso V, Griffin T. Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. Cancer Res. 1981;41:2073. [PubMed] [Google Scholar]
  • 21.Rosenberg SA, Lotze MT, Muul LM, Laitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shilani E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  • 22.Scott CF, Lambert JM, Kalish RS, Morimoto C, Schlossman SF. Human T cell can be directed to lyse tumour targets through the alternative activation/T11-E rosette receptor pathway. J Immunol. 1988;140:8. [PubMed] [Google Scholar]
  • 23.Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. 1985;314:628. doi: 10.1038/314628a0. [DOI] [PubMed] [Google Scholar]
  • 24.Steinbuck M, Andran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys. 1969;134:279. doi: 10.1016/0003-9861(69)90285-9. [DOI] [PubMed] [Google Scholar]
  • 25.Stevenson GT, Glennie MJ, Paul FE, Stevenson FK, Watts HF, Wyeth P. Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells. Biosci Rep. 1985;5:991. doi: 10.1007/BF01119911. [DOI] [PubMed] [Google Scholar]
  • 26.Stuchbury T, Shipton M, Norris R, Malthouse JPG, Brocklehurst K, Herbert JAL, Suschitzky H. A reporter group delivery system with both absolute and selective specificity for thiol groups and an improved fluorescent probe containing the 7-nitrobenzo-2-oxa-1,3-diazole moiety. Biochem J. 1975;151:417. doi: 10.1042/bj1510417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Titus JA, Garrido MA, Hecht TT, Winkler DF, Wunderlich JR, Segal DM. Human T cells targeted with anti-T3 cross-linked to antitumour antibody prevent tumour growth in nuce mice. J Immunol. 1987;138:4018. [PubMed] [Google Scholar]
  • 28.Titus JA, Perez P, Kaubisch A, Garrido MA, Segal DM. Human K/natural killer cells targeted with heterocross-linked antibodies specifically lyse tumour cells in vitro and prevent tumour growth in vivo. J Immunol. 1987;139:3153. [PubMed] [Google Scholar]
  • 29.West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES